A new study in the Journal of Clinical Oncology identifies an increased role for physicians in boosting human papillomavirus (HPV) vaccination rates among childhood cancer survivors to reduce their risk of a second cancer.
A new study in the Journal of Clinical Oncology identifies an increased role for physicians in boosting human papillomavirus (HPV) vaccination rates among childhood cancer survivors to reduce their risk of a second cancer.
The study surveyed 982 childhood cancer survivors (the majority whom were leukemia/lymphoma survivors), aged 9 to 26 years, who had completed treatment between 1 and 5 years prior to the survey. The survey touched on:
The results drawn on the HPV vaccination rates, based on the survey, were consequently compared with the vaccine initiation rates in the general population. More than a 1.5-fold difference was noted between the 2 populations: a 24% vaccination rate among the childhood cancer survivors, compared with 40% in the general-population peers. Males, overall, were more likely to get vaccinated.
The biggest difference, the study noted, was among teens 13 to 17 years of age: 22% for cancer survivors, compared with 42% for the general-population peers. However, the numbers were at par in the older population (18 to 26 years old): 25% for survivors and 24% for the general-population peers.
With nearly 7 million adolescents and young children infected with HPV annually, the virus has a significant bearing on the incidence of cervical cancers and many oral, anal, vaginal, vulvar, and penile cancers. Childhood cancer survivors are particularly susceptible to HPV infection due to their already weakened immune system post cancer treatment. This has led organizations like the American Society of Clinical Oncology to recommend that girls, as well as boys, should be vaccinated against HPV to reduce the incidence of cancer.
The current study identified lack of physician recommendation as being the biggest barrier to vaccination: 72% did not get a recommendation at all and only 5% of those surveyed ended up getting vaccinated. The most important finding was that, of the 28% who received a recommendation from their physicians, more than half got vaccinated.
“This study shows that an effective, affordable, and widely available tool for cancer prevention is being underutilized by survivors of childhood cancer,” said study author James Klosky, PhD, ABPP, an associate member at St. Jude Children’s Research Hospital in Memphis, Tennessee, in a statement. “As clinicians, we need to initiate more conversations about HPV vaccination, especially with childhood cancer survivors because they stand to benefit even more than their peers.”
Next steps, according to Klosky, are to develop interventions that would ensure clear communication between a patient’s survivorship and primary healthcare teams so that appropriate measures are in place for care continuity.
Reference
Klosky JL, Hudson MM, Chen Y, et al. Human papillomavirus vaccination rates in young cancer survivors [published online August 24, 2017]. J Clin Oncol. doi: 10.1200/JCO.2017.74.1843.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More